1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

  • October 2018
  • 85 pages
  • ID: 5780012
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

Spend on breast cancer medicines is a high-level concern for payers, but few access restrictions are in place

Despite a high level of concern regarding spend on breast cancer medicines, access restrictions remain only mild to moderate. Spend in the indication is in the top three in oncology due to both medicines’ cost and high disease prevalence; however, most payers have not implemented access restrictions. Some European payers have narrowed patient populations eligible for reimbursement, but most are in line with clinical trial inclusion and exclusion criteria, while US payers report an especially challenging environment to control access to breast cancer medicines. Payers also note cultural factors such as sensitivities and public image regarding this indication that limit their willingness to propose access restrictions, for fear of public backlash.

Selection of preferred CDK 4/6 inhibitors based on pricing may occur in the future

The selecting of preferred breast cancer medicines, including within the class of CDK 4/6 inhibitors, is not common, despite the high spend in the indication. Payers affirm that it is still too early to state preferences, and they have instead sought deeper discounts to reduce spending. German payers obtained a national rebate of 50% for the price of Ibrance, with an additional confidential discount. Meanwhile, Spanish payers have national cap agreements for Kisqali and for Ibrance, with additional caps and discounts at regional and local levels, respectively. With growing competition, some payers may begin to restrict access and select one or two preferred agents as a means of controlling expenditure.

Price and safety will be key determinants of preferred CDK 4/6 inhibitors

Without head-to-head trials, decisions as to the preferred CDK 4/6 inhibitors – Ibrance, Kisqali, or Verzenio – will be based on price and safety attributes. Ibrance’s first-to-market status and greater familiarity among physicians, coupled with an acceptable safety profile, will give the drug an advantage over the later entrants. Meanwhile, Kisqali’s cardiac testing requirements will reduce its chances of securing a preferred formulary position unless Novartis offers impressive discounts over its competitors. Payers may use soft control measures, such as advocating for the most inexpensive option after accounting for clinical needs, rather than blunt-force formulary exclusions.

Long survival times necessitate the use of intermediary endpoints such as PFS2, and time to subsequent therapy or chemotherapy

Long patient survival times in breast cancer present a further challenge to the collection of overall survival data, but intermediary endpoints could help support value propositions in the interim. Payers and regulators are increasingly more open to the use of PFS2 (the time from randomization to objective tumor progression on the next line of treatment or death from any cause) or time to subsequent therapy in both regulatory and reimbursement evaluations, especially due to the recent EMA guidance. Going forward, the endpoints will gain increasing importance with growing treatment complexity and products targeting early breast cancer. Manufacturers that invest in such evidence development could secure a better positioning in the treatment algorithm.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Oncology Partnering 2014-2019: Deal trends, players and financials

Global Oncology Partnering 2014-2019: Deal trends, players and financials

  • $ 3495
  • November 2019

The Global Oncology Partnering 2014-2019: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading ...

UK Hospital Cancer Diagnostics Market Forecasts for Major Tumor Markers: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

UK Hospital Cancer Diagnostics Market Forecasts for Major Tumor Markers: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

  • $ 2500
  • November 2019

UK Hospital Cancer Diagnostics Market Forecasts for Major Tumor Markers: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation ReviewThis new report from  Leadi ...

Germany Hospital Tumor Marker Forecasts for Major Tests: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

Germany Hospital Tumor Marker Forecasts for Major Tests: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

  • $ 2500
  • November 2019

Germany Hospital Tumor Marker Forecasts for Major Tests: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation ReviewThis new report contains 530 pages, 40 tables, and ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on